亚太药业
(002370)
| 流通市值：21.88亿 | | | 总市值：21.88亿 |
| 流通股本：6.25亿 | | | 总股本：6.25亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 306,835,789.08 | 221,933,271.08 | 112,712,517.95 | 420,643,619.24 |
| 营业收入 | 306,835,789.08 | 221,933,271.08 | 112,712,517.95 | 420,643,619.24 |
| 二、营业总成本 | 327,680,456.45 | 228,077,115.52 | 114,454,069.55 | 484,468,251.62 |
| 营业成本 | 211,419,192.11 | 151,267,862.46 | 75,876,115.38 | 285,645,963.97 |
| 税金及附加 | 4,651,222.77 | 2,963,984.05 | 1,216,517.1 | 6,138,725.83 |
| 销售费用 | 44,107,484.18 | 29,538,330.53 | 14,316,311 | 76,612,850.83 |
| 管理费用 | 40,838,470.04 | 25,687,687.06 | 13,198,118.31 | 60,846,849.85 |
| 研发费用 | 10,253,111.79 | 7,145,935.77 | 4,643,430.6 | 21,794,853.52 |
| 财务费用 | 16,410,975.56 | 11,473,315.65 | 5,203,577.16 | 33,429,007.62 |
| 其中:利息费用 | 26,373,771.94 | 17,966,682.99 | 8,929,217.04 | 47,457,830.49 |
| 其中:利息收入 | 7,048,156.62 | 6,500,306.62 | 3,730,714.88 | 14,049,318.06 |
| 加:公允价值变动收益 | 1,045,841.69 | -2,765,571.79 | -1,393,706.46 | 1,779,788.36 |
| 加:投资收益 | 15,853,845.06 | 14,683,325.57 | - | 2,034,199.38 |
| 资产处置收益 | - | - | - | 395,073.76 |
| 资产减值损失(新) | -1,867,352.1 | -1,867,352.1 | -872,535.6 | -7,565,815.83 |
| 信用减值损失(新) | 83,839.38 | 148,419.83 | 402,786.94 | -628,110.36 |
| 其他收益 | 2,525,907.61 | 1,112,719.51 | 397,564.04 | 4,356,206.68 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -3,202,585.73 | 5,167,696.58 | -3,207,442.68 | -63,453,290.39 |
| 加:营业外收入 | 122,290 | 115,000 | - | 51,964,724.65 |
| 减:营业外支出 | 222,358.49 | 222,358.49 | - | 75,111.84 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,302,654.22 | 5,060,338.09 | -3,207,442.68 | -11,563,677.58 |
| 减:所得税费用 | 156,876.25 | -414,835.77 | -209,055.97 | 313,288.34 |
| 六、净利润 | -3,459,530.47 | 5,475,173.86 | -2,998,386.71 | -11,876,965.92 |
| 持续经营净利润 | -3,459,530.47 | 5,475,173.86 | -2,998,386.71 | -11,876,965.92 |
| 归属于母公司股东的净利润 | -3,459,530.47 | 5,475,173.86 | -2,998,386.71 | -11,876,965.92 |
| (一)基本每股收益 | -0.01 | 0.01 | 0 | -0.02 |
| (二)稀释每股收益 | -0.01 | 0.01 | 0 | -0.02 |
| 八、其他综合收益 | 598,381.19 | 598,381.19 | - | - |
| 归属于母公司股东的其他综合收益 | 598,381.19 | 598,381.19 | - | - |
| 九、综合收益总额 | -2,861,149.28 | 6,073,555.05 | -2,998,386.71 | -11,876,965.92 |
| 归属于母公司股东的综合收益总额 | -2,861,149.28 | 6,073,555.05 | -2,998,386.71 | -11,876,965.92 |
| 公告日期 | 2024-10-31 | 2024-08-24 | 2024-04-27 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |